Healthy adolescents aged 15–19 years are recommended to receive MenACWY vaccine

Healthy adolescents aged 15–19 years are recommended to receive a single dose of any MenACWY vaccine.

MenACWY vaccine is funded through the NIP for all adolescents aged 14-16 years. For details see the National Immunisation Program Schedule.

There is no preference for either brand of MenACWY vaccine - MenQuadfi, Menveo or Nimenrix – for adolescents aged 15-19 years.

Healthy adolescents who have received a dose of MenACWY vaccine in the past for other reasons — such as travel to a country where meningococcal disease is common — may or may not need a dose of MenACWY vaccine when they turn 15 years of age. The clinical need for a dose of MenACWY vaccine in these adolescents can be assessed on a case-by-case basis. Receiving an additional dose of vaccine is not harmful.

Healthy adolescents who have received a dose of quadrivalent meningococcal polysaccharide vaccine in the past (such as Mencevax or Menomune; previously available in Australia but now discontinued) should receive a dose of conjugate MenACWY vaccine at age 15–19 years. MenACWY vaccine should be given at least 6 months after the dose of quadrivalent meningococcal polysaccharide vaccine.